UCB Selects Georgia for New U.S. Biologics Manufacturing Facility; ~$5B Economic Impact and ~330 Permanent Jobs

• New Gwinnett County facility will strengthen UCB’s global biologics manufacturing network and support growing demand across its portfolio and pipeline

Brussels, Belgium and Atlanta, Georgia – March 24, 2026 – UCB today announced that it has selected Gwinnett County, Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient. The project represents a major milestone in UCB’s previously announced U.S. expansion and reinforces the company’s long-term commitment to patients, innovation, and sustainable growth in one of its fastest-growing markets.

Spanning approximately 460,000 square feet or roughly the size of eight football fields, the state-of-the-art campus will sit on 79 acres and is designed to be a cornerstone of UCB’s global biologics manufacturing network. Once operational, the facility is expected to produce complex Biologics 24/7 primarily for the U.S. market. In combination with UCB’s global network, the facility will strengthen UCB Supply resilience globally while the new campus will serve as a hub for our U.S. Manufacturing Operations, underscoring our long-term commitment to the U.S. 

The new facility will:

• Strengthen UCB’s global biologics manufacturing network
• Enhance supply chain resilience
• Support growing demand for its biologics portfolio and future pipeline

A Strategic Investment in Long-Term Growth

The Georgia investment reinforces UCB’s decade-plus growth strategy, underpinned by strong execution, long-dated patent protection, and continued investment in differentiated innovation. It reflects UCB’s commitment to investing ahead of demand while maintaining strategic flexibility in an evolving global environment.

UCB has achieved 15 FDA approvals or indication expansions, nine of which were secured in the past three years, demonstrating sustained scientific progress and commercial delivery for people living with severe diseases.

“This decision reflects our confidence in UCB’s long-term growth and our deep-rooted commitment to the United States,” said Jean-Christophe Tellier, UCB CEO. “By investing in Gwinnett County and the Rowen Foundation in Georgia, where our U.S. headquarters have been based for more than three decades, we are strengthening our biologics manufacturing capabilities, supporting our innovation pipeline, and creating high-quality jobs in a state that offers outstanding talent, a strong manufacturing tradition, and an ecosystem designed for sustainable, long-term success. This project is expected to generate approximately $5 billion in total economic impact, reflecting the broader value it will create for the region and its communities.”

Rowen Development in Gwinnett County

Within Georgia, where UCB already has its U.S. headquarters, UCB has selected Rowen Development in Gwinnett County as the site for the new biologics manufacturing facility.  

Rowen offers:

• A scalable site within a master-planned innovation district
• Strong infrastructure access
• Efficient permitting processes
• Participation in a growing life sciences and advanced manufacturing ecosystem

Located in the Atlanta metropolitan area—between Georgia Tech and the University of Georgia—the site provides access to a deep and expanding talent pool across science, engineering, and advanced manufacturing. The surrounding community also offers a strong quality of life and a rapidly growing workforce to support world-class manufacturing capabilities.

“When we met with UCB leadership earlier this year in Belgium, we discussed how the Peach State would be the right partner for their visionary plans in the U.S. that will benefit both patients and hardworking Georgians,” said Governor Brian Kemp. “UCB’s announcement is also a significant milestone for our life sciences industry, representing one of the largest investments in state history and establishing both the Rowen facility and Georgia as a true hub of innovation in this field.”

Economic Impact and Job Creation

The significant investment is expected to generate approximately $5 billion in total economic impact, including:

• Around 330 permanent highly skilled jobs
• More than 1000 construction jobs

“As we execute on our strategy of growth, this manufacturing site will support the commercial production of recently approved and future pipeline medicines, bringing them closer to patients and representing the full depth of our patient value chain, from research, to development, to commercial, and manufacturing operations in the U.S.,” said Taco van Tiel, Head of UCB in the U.S. “UCB currently employs around 2,000 people in the U.S., who are striving every day to reach as many people that can benefit from our innovative medications as possible, and this new campus further contributes to elevating the lives of the patients and caregivers we serve.”

UCB in the United States

UCB’s presence in the United States spans nearly a century. The company has been active in the U.S. since the 1930s and established its U.S. headquarters in Atlanta in 1993, which today serves as a central hub for commercial, research, and corporate operations. Since 2017, UCB’s U.S. workforce has grown by 73%, including a 121% increase in R&D roles, bringing the company’s U.S. employee base to nearly 2,000 people.